Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

25.73B

Market cap25.73B

Price-Earnings ratio

20.47

Price-Earnings ratio20.47

Dividend yield

—

Dividend yield—

Average volume

1.38M

Average volume1.38M

High today

$180.06

High today$180.06

Low today

$175.04

Low today$175.04

Open price

$177.81

Open price$177.81

Volume

481.73K

Volume481.73K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$110.04

52 Week low$110.04

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $175.31. The company's market cap stands at 25.73B, with a P/E ratio of 20.47.

As of 2026-04-09, Biogen(BIIB) stock has fluctuated between $175.04 and $180.06. The current price stands at $175.31, placing the stock +0.2% above today's low and -2.6% off the high.

The Biogen(BIIB)'s current trading volume is 481.73K, compared to an average daily volume of 1.38M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $110.04.

BIIB News

TipRanks 2d

Biogen price target lowered to $213 from $233 at RBC Capital

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Biogen (BIIB) to $213 from $233 and keeps an Outperform rating on the shares as part of th...

Simply Wall St 2d

Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook

Biogen (NasdaqGS:BIIB) has agreed to acquire Apellis Pharmaceuticals, adding two commercial immunology and rare disease products to its portfolio. The company...

Nasdaq 3d

Why Biogen Stock Got Mashed on Monday

Key Points Management aims to book a $34 million charge in the quarter. This is due to loftier anticipated spend on items such as milestone payments and resea...

Analyst ratings

50%

of 36 ratings

Buy

44.4%

Hold

50%

Sell

5.6%

More BIIB News

Nasdaq 3d

American Water Works Takes Over #314 Spot From Biogen

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, American Water Works Co, Inc. (Symbol: AWK) has taken o...

Benzinga 3d

Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) shares experienced a sharp reversal as the stock’s momentum score jumped from 8.36 to 95.26 on a week-over-week basis...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.